Singapore, 1 November 2016 - Roche Pharmaceuticals Asia Pacific announces that Dr. Christiane Hamacher has assumed the role of Head of Asia Pacific (APAC), joining Roche's global Pharmaceutical Leadership Team.
Christiane joined Roche in 2007 and was most recently General Manager of Roche Pharmaceuticals' Czech Republic business. Christiane has established a strong track record in strategic management and human resources, and has undertaken global commercial and operational roles in the US, Europe and Asia. At Roche, Christiane's roles have included the positions of General Manager Norway, Life Cycle Leader, Virology and Resourcing Manager in Group Human Resources. Prior to joining Roche, Christiane spent 10 years at Schering AG where she held senior managerial positions in oncology, human resources and was General Manager Philippines. Christiane received a PhD in Molecular Biology from the Ruhr University of Bochum, Germany.
In her new role, Dr. Hamacher will assume responsibility for the development and commercialisation of Roche Pharmaceuticals' innovative portfolio of medicines across APAC. Christiane will be based in Singapore, the Company's regional headquarters, and will lead more than 6,000 employees in 22 countries across the region.
Commenting on her appointment, Dr. Christiane Hamacher said: "I am delighted to take up my new position as Head of APAC for Roche Pharmaceuticals Business. The region is of great importance to Roche and I am excited by the opportunities available to our business and our patients. Our success in Asia Pacific is founded upon our commitment to being one of the innovation-driven leaders in healthcare and I look forward to working closely with my colleagues to build on that success as we prepare for the launch of a number of innovative medicines throughout the region."
Christiane succeeds Alexander Hardy who was appointed Head of Global Product Strategy based in Switzerland.
Emma Thompson/Stephanie Tan
T: +65 6340 7287
Email: [email protected]
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.